SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).METHODSPatients with …@SWOG 1815, a randomized phase 3 study comparing gem/cis/nab-paclitaxel versus gem/cis in BTC: no improvement in OS and additive toxicity with a triplet. Intriguing signal in locally advanced patients and GB cancer.
